Alaxia, company created in April 2008, develops an anti-inflammatory and anti-bacterial new treatment for cystic fibrosis: Meveol®.

Meveol® has been recently granted orphan drug status by both EU Medicinal Agency (EMA) and US Food and Drug Agency (FDA).

Alaxia selected the IdehalerPocket® for Meveol® nebulization.

The Meveol® in association with the IdehalerPocket® is a new advance for the cystic fibrosis treatment and for the life quality of cystic fibrosis patients.



Press releases

TLM French regional channel
2’05" Bertrand Frachon